Tislelizumab Injection

Tislelizumab injection is an immune-targeted drug. Its main clinical indications are:
It is suitable for the treatment of relapsed or refractory classical Hodgkin lymphoma after at least second-line systemic chemotherapy.
It is suitable for the treatment of locally advanced or metastatic urothelial carcinoma that has progressed within 12 months of neoadjuvant or adjuvant chemotherapy after failure of platinum-based chemotherapy with high PD-L1 expression.
The above indications were conditionally approved based on objective response rate and response duration results from a single-arm clinical trial, respectively. Full approval for the above indications will depend on whether planned confirmatory randomized controlled clinical trials can demonstrate a significant clinical benefit of treatment with this product compared with standard treatment.